Ilkka Rauma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ilkka Rauma has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Hanna Kuusisto
Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland
7 shared publications Hanna Kuusisto
Tampere University Hospital, Department of Neurology, Tampere, Finland; University of Eastern Finland, Department of Health and Social Management, Kuopio, Finland
4 shared publications- Marja Niiranen
Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland
3 shared publications Tiina Mustonen
Neuro Center, Kuopio University Hospital, Kuopio, Finland
3 shared publicationsAnne M. Remes
University of Oulu, Research Unit of Clinical Neuroscience, P.O. Box 8000, 90014, University of Oulu, Finland; Northern Ostrobothnia Hospital District, MRC Oulu, P.O. Box 8000, 90014 University of Oulu, Finland
2 shared publicationsIiro Korhonen
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 65, 15-20
Pediatric-onset multiple sclerosis in Finland
- 23 September 2026
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 65, 15-20
Open AccessPediatric-onset multiple sclerosis in Finland
- Open Access
- 8 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 119
Adult-onset and late-onset multiple sclerosis in older adults in a Finnish university hospital
Background: The clinical characteristics of multiple sclerosis (MS) in individuals aged 65 years and older remain scarcely studied. This retrospective study compared late-onset MS (LOMS, onset ≥ 50 years) and adult-onset MS (AOMS, onset 18–49 years) in older adults with MS (OAwMS) aged ≥ 65 years. Methods: Data of subjects aged ≥ 65 years with a confirmed MS diagnosis and a recorded age at onset were collected from the Finnish MS registry at Tampere University Hospital, excluding individuals with paediatric-onset MS. Demographics, disease-modifying therapy (DMT) use, relapse history and Expanded Disability Status Scale (EDSS) scores were compared between LOMS and AOMS groups. Results: The cohort included 248 subjects (41 LOMS, 207 AOMS). Primary progressive MS (PPMS) was more common in LOMS when compared to AOMS (41.5% vs. 12.6% at data acquisition, p < 0.001). Among subjects with a history of relapsing-remitting MS (RRMS) (32 LOMS, 178 AOMS), DMT had been used by 25.0% and 27.5% of subjects with LOMS and AOMS, and relapses after age 65 occurred in 18.8% and 7.3% of subjects with LOMS and AOMS, respectively. Subjects with LOMS discontinued DMT at an older age when compared to those with AOMS (mean 64.0 vs. 58.8 years, p = 0.04). No age-related differences in EDSS were observed after age 65. Conclusions: PPMS was more common among subjects with LOMS. Among subjects with a current or previous diagnosis of RRMS, occasional relapses were observed after age 65 in both groups, though multiple relapses were rare. These findings support the need for individualised care of OAwMS.
- 8 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 119
Open AccessAdult-onset and late-onset multiple sclerosis in older adults in a Finnish university hospital
Background: The clinical characteristics of multiple sclerosis (MS) in individuals aged 65 years and older remain scarcely studied. This retrospective study compared late-onset MS (LOMS, onset ≥ 50 years) and adult-onset MS (AOMS, onset 18–49 years) in older adults with MS (OAwMS) aged ≥ 65 years. Methods: Data of subjects aged ≥ 65 years with a confirmed MS diagnosis and a recorded age at onset were collected from the Finnish MS registry at Tampere University Hospital, excluding individuals with paediatric-onset MS. Demographics, disease-modifying therapy (DMT) use, relapse history and Expanded Disability Status Scale (EDSS) scores were compared between LOMS and AOMS groups. Results: The cohort included 248 subjects (41 LOMS, 207 AOMS). Primary progressive MS (PPMS) was more common in LOMS when compared to AOMS (41.5% vs. 12.6% at data acquisition, p < 0.001). Among subjects with a history of relapsing-remitting MS (RRMS) (32 LOMS, 178 AOMS), DMT had been used by 25.0% and 27.5% of subjects with LOMS and AOMS, and relapses after age 65 occurred in 18.8% and 7.3% of subjects with LOMS and AOMS, respectively. Subjects with LOMS discontinued DMT at an older age when compared to those with AOMS (mean 64.0 vs. 58.8 years, p = 0.04). No age-related differences in EDSS were observed after age 65. Conclusions: PPMS was more common among subjects with LOMS. Among subjects with a current or previous diagnosis of RRMS, occasional relapses were observed after age 65 in both groups, though multiple relapses were rare. These findings support the need for individualised care of OAwMS.
- Open Access
- 17 September 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 258, 109164
Clinical characteristics of multiple sclerosis in older adults in a Finnish Tertiary Centre
- 17 September 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 258, 109164
Open AccessClinical characteristics of multiple sclerosis in older adults in a Finnish Tertiary Centre
- Open Access
- 4 September 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106724
The real-world efficacy of Cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland – A follow-up study after four years of observation
- 4 September 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106724
Open AccessThe real-world efficacy of Cladribine tablets and treatment persistence in people with highly active relapsing multiple sclerosis in Finland – A follow-up study after four years of observation
- Open Access
- 1 July 2025
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 11 (3)
Delays in treatment initiation for patients with relapsing-remitting multiple sclerosis—A nationwide population-based study
Background: Early disease-modifying therapy (DMT) improves outcomes in patients with relapsing-remitting multiple sclerosis (pwRRMS), but reasons for delayed or absent initiation are unclear. Objective: To investigate reasons and trends for delayed or absent DMT initiation among Finnish pwRRMS. Methods: A nationwide retrospective study using the Finnish MS Registry identified 2363 pwRRMS diagnosed between 2010 and 2019 in the participating centers. Patients never receiving DMT or starting >2 years post-diagnosis were compared to those initiating DMT within a year of diagnosis. Results: We identified 193 pwRRMS who never started DMT, 88 had delayed initiation over 2 years, and 1944 started within a year. The no/delayed DMT group was older at diagnosis (mean 38.7 vs 35.2 years, p < 0.001). Corticosteroid-treated relapses were more frequent among early initiators. Optic neuritis was more common in patients with delayed or no DMT. Treatment refusal was the primary reason for delayed/no DMT (35.6%), with 68% of refusers never starting. From 2010to 2019, delayed/no DMT initiation ( p = 0.007) and treatment refusal ( p = 0.004) decreased significantly. Conclusion: Delayed or absent DMT initiation is linked to older age, optic neuritis, disease inactivity, and treatment refusal, which declined over time, likely due to expanded DMT options.
- 1 July 2025
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 11 (3)
Open AccessDelays in treatment initiation for patients with relapsing-remitting multiple sclerosis—A nationwide population-based study
Background: Early disease-modifying therapy (DMT) improves outcomes in patients with relapsing-remitting multiple sclerosis (pwRRMS), but reasons for delayed or absent initiation are unclear. Objective: To investigate reasons and trends for delayed or absent DMT initiation among Finnish pwRRMS. Methods: A nationwide retrospective study using the Finnish MS Registry identified 2363 pwRRMS diagnosed between 2010 and 2019 in the participating centers. Patients never receiving DMT or starting >2 years post-diagnosis were compared to those initiating DMT within a year of diagnosis. Results: We identified 193 pwRRMS who never started DMT, 88 had delayed initiation over 2 years, and 1944 started within a year. The no/delayed DMT group was older at diagnosis (mean 38.7 vs 35.2 years, p < 0.001). Corticosteroid-treated relapses were more frequent among early initiators. Optic neuritis was more common in patients with delayed or no DMT. Treatment refusal was the primary reason for delayed/no DMT (35.6%), with 68% of refusers never starting. From 2010to 2019, delayed/no DMT initiation ( p = 0.007) and treatment refusal ( p = 0.004) decreased significantly. Conclusion: Delayed or absent DMT initiation is linked to older age, optic neuritis, disease inactivity, and treatment refusal, which declined over time, likely due to expanded DMT options.
- Open Access
- 22 August 2024
- Published by IOS Press
- Vol. 316, 1967-1971
Patient Selection Is the Key for Successful Video Appointments: Lessons Learned from the COVID-19 Pandemic
The use of video appointments (VAs) increased significantly during the COVID-19 pandemic. This study investigated the evolution of VA utilisation in Finland using data from two surveys conducted in 2021 (40 responses) and 2023 (30 responses). Our primary aim was to identify patient groups best suited for VAs. Respondents were either neurologists or neurologists-in-training. Our findings suggest that patients with epilepsy or headaches are most suitable for VAs. VAs were primarily used for follow-up visits during both survey periods, but their application for first visits decreased from 68.20% in 2021 to 27.80% in 2023. Healthcare professionals’ concerns about data protection have diminished over time, but there is still need for enhanced training in the use of remote applications. Future research should focus on validating the cost-effectiveness, data security and timeliness of VAs.
- 22 August 2024
- Published by IOS Press
- Vol. 316, 1967-1971
Open AccessPatient Selection Is the Key for Successful Video Appointments: Lessons Learned from the COVID-19 Pandemic
The use of video appointments (VAs) increased significantly during the COVID-19 pandemic. This study investigated the evolution of VA utilisation in Finland using data from two surveys conducted in 2021 (40 responses) and 2023 (30 responses). Our primary aim was to identify patient groups best suited for VAs. Respondents were either neurologists or neurologists-in-training. Our findings suggest that patients with epilepsy or headaches are most suitable for VAs. VAs were primarily used for follow-up visits during both survey periods, but their application for first visits decreased from 68.20% in 2021 to 27.80% in 2023. Healthcare professionals’ concerns about data protection have diminished over time, but there is still need for enhanced training in the use of remote applications. Future research should focus on validating the cost-effectiveness, data security and timeliness of VAs.
- Open Access
- 19 March 2022
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 61, 103755
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study
- 19 March 2022
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 61, 103755
Open AccessFinnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study
- Open Access
- 13 July 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (2) , 824-835
Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
Background: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives: To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods: In this retrospective case series study, we analyzed the data of all but two MS patients who had received alemtuzumab in Finland until 2019. Data were systematically collected from patient files. Results: Altogether 121 patients were identified, most of whom had received previous DMTs (82.6%). Median follow-up time after treatment initiation was 30.3 months and exceeded 24 months in 78 patients. Infusion-associated reactions (IARs) were observed in 84.3%, 57.3%, and 57.1% of patients during alemtuzumab courses 1–3, respectively. Serious adverse events (SAEs) were observed in 32.2% of patients, serious IARs in 12.4% of patients, and SAEs other than IARs in 23.1% of patients. Autoimmune adverse events were observed in 30.6% of patients. One patient died of hemophagocytic lymphohistiocytosis, and one patient died of pneumonia. A previously unreported case of thrombotic thrombocytopenic purpura was documented. Conclusions: SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.
- 13 July 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (2) , 824-835
Open AccessSafety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
Background: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives: To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods: In this retrospective case series study, we analyzed the data of all but two MS patients who had received alemtuzumab in Finland until 2019. Data were systematically collected from patient files. Results: Altogether 121 patients were identified, most of whom had received previous DMTs (82.6%). Median follow-up time after treatment initiation was 30.3 months and exceeded 24 months in 78 patients. Infusion-associated reactions (IARs) were observed in 84.3%, 57.3%, and 57.1% of patients during alemtuzumab courses 1–3, respectively. Serious adverse events (SAEs) were observed in 32.2% of patients, serious IARs in 12.4% of patients, and SAEs other than IARs in 23.1% of patients. Autoimmune adverse events were observed in 30.6% of patients. One patient died of hemophagocytic lymphohistiocytosis, and one patient died of pneumonia. A previously unreported case of thrombotic thrombocytopenic purpura was documented. Conclusions: SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.
- 29 July 2020
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 15 (4) , 567-569
Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients
Fingolimod reduces inflammatory activity in multiple sclerosis (MS) by acting as a functional antagonist of sphingosine 1-phosphate (S1P) receptors. It has been suggested that S1P might also contribute to the antiatherogenic effect of high-density lipoprotein (HDL). We conducted a retrospective observational study using data of 72 MS patients from two Finnish hospital districts to find out whether lipid profiles change during treatment with fingolimod. A mixed-effects model with patient as a random effect was used to analyze lipid profile alterations. We found a statistically significant elevation in both total cholesterol (0.12 mmol/L per year) and HDL (0.04 mmol/L per year) during a median follow-up of 12 months, while low-density lipoprotein (LDL) and triglycerides remained unchanged. Since the mean elevation observed in both lipid values seems to be modest, we suggest that routine lipid profile monitoring is unnecessary during fingolimod treatment in MS patients without pre-existing cardiovascular comorbidities. Graphical abstract
- 29 July 2020
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 15 (4) , 567-569
Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients
Fingolimod reduces inflammatory activity in multiple sclerosis (MS) by acting as a functional antagonist of sphingosine 1-phosphate (S1P) receptors. It has been suggested that S1P might also contribute to the antiatherogenic effect of high-density lipoprotein (HDL). We conducted a retrospective observational study using data of 72 MS patients from two Finnish hospital districts to find out whether lipid profiles change during treatment with fingolimod. A mixed-effects model with patient as a random effect was used to analyze lipid profile alterations. We found a statistically significant elevation in both total cholesterol (0.12 mmol/L per year) and HDL (0.04 mmol/L per year) during a median follow-up of 12 months, while low-density lipoprotein (LDL) and triglycerides remained unchanged. Since the mean elevation observed in both lipid values seems to be modest, we suggest that routine lipid profile monitoring is unnecessary during fingolimod treatment in MS patients without pre-existing cardiovascular comorbidities. Graphical abstract